• Cullinan Therapeutics flagged planned interim results from the Phase 3 REZILIENT3 trial for future presentation at IASLC WCLC 2026.
• The study tests zipalertinib with chemotherapy versus chemotherapy alone as first-line treatment for EGFR exon 20 insertion-positive NSCLC.
• Selection for the conference’s Presidential Symposium signals the data could be clinically meaningful, with potential to influence treatment practice.
• The presentation is scheduled for Sept. 14, 2026, in Seoul.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819883527) on August 19, 2026, and is solely responsible for the information contained therein.